Aarti Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019
October 23, 2019 at 08:29 am EDT
Share
Aarti Drugs Limited announced earnings results for the second quarter ended September 30, 2019. For the second quarter, the company announced sales was INR 4,775.000 million compared to INR 3,474.100 million a year ago. Net income was INR 323.100 million compared to INR 180.500 million a year ago. Basic earnings per share was INR 13.87 compared to INR 7.65 a year ago. For the half year, sales was INR 8,829.300 million compared to INR 7,217.000 million a year ago. Net income was INR 547.600 million compared to INR 414.200 million a year ago. Basic earnings per share was INR 23.41 compared to INR 17.57 a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
